Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion
AssigneeThe Johns Hopkins University
InventorsDavid M. Sabatini, Hediye Erdjument-Bromage, Mary Lui, Paul Tempst, Solomon H. Snyder
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Johns Hopkins University
InventorsDavid M. Sabatini, Hediye Erdjument-Bromage, Mary Lui, Paul Tempst, Solomon H. Snyder
Estimating the term…
A protein complex containing 245 kDa and 35 kDa components, designated RAFT1 and RAFT2 (for Rapamycin And FKBP12 Target) interacts with FKBP12 in a rapamycin-dependent manner. This interaction has the pharmacological characteristics expected from the observed in vivo effects of rapamycin: it occurs at low nanomolar concentrations of rapamycin and is competed by excess FK506. Sequences (330 amino acids total) of tryptic peptides derived from the affinity purified 245 kDa RAFT1 reveals striking homologies to the predicted products of the yeast TOR genes, which were originally identified by mutations that confer rapamycin resistance in yeast. A RAFT1 cDNA was obtained and found to encode a 289 kDa protein (2550 amino acids) that is 43% and 39% identical to TOR2 and TOR1, respectively.
A rat RAFT1 protein prepared by the process of:
An isolated and purified RAFT1 protein having the amino acid sequence as shown in SEQ ID NO:1, wherein the acronym RAFT connotes a rapamycin and FKBP12 target.
Dependencies are inferred from the claim text.